ScandiNova contributes to increased availability of cancer therapy – Over 25,000 treatments per day with ScandiNova's modulator
ScandiNova is a world leader in developing and manufacturing high-voltage pulse modulators that are used, among other things, as a power source in radiotherapy systems for treatment of cancer.
In total, there are more than 15,000 radiotherapy systems installed in hospitals worldwide. Leading manufacturers are Varian Medical Systems, Elekta and Accuray, but there are many more players with different applications and specialist areas. Today, ScandiNova is a partner and supplier to most companies in the markets in the USA, Europe, and Asia.
A major challenge for manufacturers of radiotherapy systems is the increased worldwide demand for access to cancer treatment, which requires both new technologies and reliable systems that are easy to install, use and maintain.
The pulse modulator, which can be considered as the power source, is a key component of a radiotherapy system. It is the pulse modulator which generates power to accelerate the particles (usually electrons, but in some cases also protons) that irradiate the cancer tumour and treat the patient.
Historically, most manufacturers of radiotherapy systems have used PFN (Pulse Forming Network) based pulse modulators with electron tubes (thyratrons). ScandiNova is leading the way in replacing these with modern semiconductor-based modulators that have significantly longer lifetimes, higher uptime, better energy efficiency and take up less space. Our modulators also have minimal consumables and require very limited maintenance. By that, we contribute to a higher availability of radiotherapy treatment and to the development of new methods.
ScandiNova M100, pulse modulator for integration into radio therapy systems
